Ajinomoto Bio-Pharma Services vs Kaneka Eurogentec: CDMO Comparison
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Kaneka Eurogentec on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Kaneka Eurogentec holds 4 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; Kaneka Eurogentec does not.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Kaneka Eurogentec qualify as Oligo/ASO manufacturers; Ajinomoto Bio-Pharma Services carries the higher composite Signal Score for Oligo/ASO programs in this comparison.
What to evaluate for Oligo/ASO programs
Both Ajinomoto Bio-Pharma Services and Kaneka Eurogentec qualify as Oligo/ASO CDMOs. When choosing between them for Oligo/ASO programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Ajinomoto Bio-Pharma Services vs Kaneka Eurogentec
How do Ajinomoto Bio-Pharma Services and Kaneka Eurogentec compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Oligo/ASO manufacturing — Ajinomoto Bio-Pharma Services or Kaneka Eurogentec?
Both Ajinomoto Bio-Pharma Services and Kaneka Eurogentec are tagged as Oligo/ASO CDMOs in our directory, so both are credible options for Oligo/ASO programs. The most important differentiator for Oligo/ASO selection is typically synthesis scale: Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Ajinomoto Bio-Pharma Services carries a Signal Score of 86/100 and Kaneka Eurogentec carries 80/100 — a small lead for Ajinomoto Bio-Pharma Services. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →